

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

PU3650USw

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/019976

PRIORITY DATE CLAIMED

30 APRIL 1999

INTERNATIONAL APPLICATION NO.

PCT/EP00/03848

INTERNATIONAL FILING DATE

28 APRIL 2000

TITLE OF INVENTION

IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS

APPLICANT(S) FOR DO/EO/US

BIGHAM, Eric Cleveland; BISHOP, Michael Joseph; DREWRY, David Harold; GARRISON, Deanna Trojan;
HODSON, Stephen Joseph; NAVAS III, Frank; SPEAKE, Jason D.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (e) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

PCT Request

PCT Publication Cover Sheet

U.S. APPLICATION NO. (IF KNOWN, SET OFF) <div style="font-size: 2em; font-weight: bold; text-align: center;">10/019576</div>	INTERNATIONAL APPLICATION NO. <div style="font-weight: bold; text-align: center;">PCT/EP00/03848</div>	ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold; text-align: center;">PU3650USw</div>
---------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1040.00
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$890.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$740.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$710.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).	<input type="checkbox"/> 20 <input type="checkbox"/> 30	\$0.00
--------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------	--------

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	25 - 20 =	5	x \$18.00		\$90.00
Independent claims	1 - 3 =	0	x \$84.00		\$0.00
					\$0.00

Multiple Dependent Claims (check if applicable). ☐

TOTAL OF ABOVE CALCULATIONS =

\$980.00	\$980.00
----------	----------

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

SUBTOTAL =

\$980.00	\$980.00
----------	----------

Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).

TOTAL NATIONAL FEE =

\$980.00	\$980.00
----------	----------

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

TOTAL FEES ENCLOSED =

\$980.00	\$980.00
----------	----------

Amount to be refunded	\$
charged	\$

a. ☐ A check in the amount of _____ to cover the above fees is enclosed.


b. ☒ Please charge my Deposit Account No. 07-1392 in the amount of \$980.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1392. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:



23347

PATENT TRADEMARK OFFICE

Robert H. Brink

SIGNATURE

ROBERT H. BRINK

NAME

36,094

REGISTRATION NUMBER

22 October 2001

DATE

Page 2 of 2

EXPRESS MAIL LABEL
NO. EL355943218US

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

PU3650USw

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/019976

PRIORITY DATE CLAIMED
30 APRIL 1999INTERNATIONAL APPLICATION NO.
PCT/EP00/03848INTERNATIONAL FILING DATE
28 APRIL 2000

TITLE OF INVENTION

IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS

APPLICANT(S) FOR DO/EO/US

BIGHAM, Eric Cleveland; BISHOP, Michael Joseph; DREWRY, David Harold; GARRISON, Deanna Trojan;
HODSON, Stephen Joseph; NAVAS III, Frank; SPEAKE, Jason D.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
 4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
 7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
 8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
 10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
 11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
 12. ☒ A copy of the International Search Report (PCT/ISA/210).
- Items 13 to 20 below concern document(s) or information included:**
13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 15. ☒ A **FIRST** preliminary amendment.
 16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
 17. ☐ A substitute specification.
 18. ☐ A change of power of attorney and/or address letter.
 19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
 20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
 21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
 22. ☒ Certificate of Mailing by Express Mail
 23. ☒ Other items or information:

PCT Request

PCT Publication Cover Sheet

Rec'd PCT/PTO 23 OCT 2001

CERTIFICATE OF MAILING "EXPRESS MAIL"

Docket No.

Applicant(s): **BIGLAM, Eric Cleveland et al.**

Rec'd PCT/PTO 23 OCT 2001
PU3650USW

Serial No.	Filing Date	Examiner	Group Art Unit
------------	-------------	----------	----------------

Invention: **IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS**

I hereby certify that this Patent Application under 35 USC 371 and corresponding papers
(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

10/23/2001
(Date)

Cynthia M. Edwards
(Typed or Printed Name of Person Mailing Correspondence)
Cynthia M. Edwards
(Signature of Person Mailing Correspondence)

EXPRESS MAIL LABEL
NO. EI395943218US (iber)

Note: Each paper must have its own certificate of mailing.

PATENT APPLICATION SERIAL NO. **10/019976**

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

01/16/2002 10000000 00000004 070000 10000000

01 00.00	00.00	00
02 00.00	00.00	00